HC Wainwright Estimates Cytosorbents FY2028 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – HC Wainwright issued their FY2028 earnings per share estimates for Cytosorbents in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst S. Lee anticipates that the medical research company will post earnings of ($0.07) per share for the year. HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ FY2029 earnings at ($0.05) EPS.

A number of other brokerages have also recently weighed in on CTSO. StockNews.com began coverage on Cytosorbents in a report on Thursday. They set a “hold” rating on the stock. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research note on Tuesday. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Stock Performance

Shares of CTSO opened at $0.97 on Friday. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company has a market cap of $53.04 million, a PE ratio of -2.69 and a beta of 0.78. The stock has a 50-day moving average price of $1.07 and a 200-day moving average price of $1.04.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.04. The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%.

Institutional Investors Weigh In On Cytosorbents

A number of large investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new stake in Cytosorbents in the 4th quarter worth approximately $30,000. Northern Trust Corp grew its position in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after acquiring an additional 16,701 shares in the last quarter. Avenir Corp boosted its stake in Cytosorbents by 4.0% during the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after buying an additional 118,387 shares during the period. Raymond James Financial Inc. bought a new stake in Cytosorbents in the fourth quarter worth about $99,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.